WAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS

WAVE Life Sciences (NASDAQ:WVE) announced its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21, FiscalAI reports. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The firm had revenue of $38.25 million for the quarter, compared to the consensus estimate of $8.45 million.

Here are the key takeaways from WAVE Life Sciences’ conference call:

• Wave is accelerating WVE-007 (INHBE GalNAc‑siRNA) into the phase II‑A multi‑dose trial this quarter after phase I showed durable Activin E suppression and a placebo‑adjusted 14.3% visceral fat reduction with lean mass preservation, supporting once‑ or twice‑year dosing and combination/maintenance strategies.
• RNA‑editing candidate WVE‑006 for AATD has produced therapeutically relevant restoration of AAT (including >20 µM during acute phase responses), will present expanded data at ATS, and management expects regulatory feedback on a possible accelerated approval pathway in mid‑2026.
• The pipeline is broadening — WVE‑008 (PNPLA3 I148M) is being advanced toward first‑in‑human studies with a planned CTA in 2026 to address an estimated 9 million homozygous carriers, and Wave is progressing bifunctional and extrahepatic programs.
• Financially, revenue rose to $38.2M and net loss narrowed to $26.1M in Q1; Wave ended the quarter with $544.6M in cash, which management says funds operations into Q3 2028.
• Clinical and regulatory uncertainty and competition remain material risks — R&D and G&A spending increased quarter‑over‑quarter, key programs are still early stage (dose‑finding and durability questions remain), and other modalities (DNA editors, combo regimens) represent competitive pressures.

WAVE Life Sciences Price Performance

WVE traded down $0.51 on Wednesday, hitting $7.02. The company had a trading volume of 1,995,258 shares, compared to its average volume of 4,288,739. The company’s fifty day moving average price is $10.28 and its 200 day moving average price is $11.27. WAVE Life Sciences has a 1-year low of $5.02 and a 1-year high of $21.73. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -5.75 and a beta of -1.32.

Insider Buying and Selling

In related news, CEO Paul Bolno sold 10,480 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the sale, the chief executive officer directly owned 275,520 shares in the company, valued at approximately $3,705,744. The trade was a 3.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chris Francis sold 33,194 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the completion of the sale, the insider owned 61,867 shares of the company’s stock, valued at approximately $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 52,373 shares of company stock valued at $757,527 in the last quarter. Company insiders own 23.98% of the company’s stock.

Institutional Trading of WAVE Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. GSK plc acquired a new stake in WAVE Life Sciences in the 4th quarter valued at approximately $310,177,000. Darwin Global Management Ltd. acquired a new stake in WAVE Life Sciences in the 4th quarter valued at approximately $125,168,000. Price T Rowe Associates Inc. MD grew its holdings in WAVE Life Sciences by 83.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after buying an additional 3,362,880 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the last quarter. Finally, Primecap Management Co. CA grew its holdings in WAVE Life Sciences by 115.7% in the 4th quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company’s stock valued at $69,620,000 after buying an additional 2,196,632 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on WVE. Truist Financial began coverage on shares of WAVE Life Sciences in a research note on Wednesday. They issued a “buy” rating and a $15.00 price target on the stock. Wedbush boosted their target price on WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Monday, April 20th. HC Wainwright cut their price target on WAVE Life Sciences from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. Finally, Wall Street Zen downgraded WAVE Life Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 12th. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.44.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.